comprehensive -WSS

comprehensive

author：fashion 2025-10-01 22:58:05 - browse：4262

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Walmart eyes Medicare Advantage provider ChenMed

hotspot

WSS

PEPFAR is under serious threat — and so is global health

What will save rural psychiatry services? Higher Medicaid payments

New weight loss drugs vying to be the next Wegovy or Mounjaro

How housing is health care on Long Island

Adam's Biotech Scorecard: Do Sarepta's exon

iTeos Therapeutics debuts first data on TIGIT

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

explore

Medical leaders decry Supreme Court decision on affirmative action

Diverse clinical trials: Why aren’t we there yet?

Trump demands the U.S. pay no more for drugs than other countries … again

Adam's Biotech Scorecard: Do Sarepta's exon

Psychedelics group wrestles with new pharma identity

Food makers tried to stack nutrition panel with preferred experts

Psychedelics group wrestles with new pharma identity

What will save rural psychiatry services? Higher Medicaid payments

Anesthesiologist group: stop taking Ozempic before surgery

Startling documents reveal new facets of Sacklers' opioid empire

leisure time

Pig kidney works a record two months in donated body

IRA could hurt research into orphan drugs for rare diseases

Biohaven protein

Lab trade group sues FDA to halt regulation of lab

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

hotspot

hotspot

focus

leisure time